Interaction of natural killer cells and sorafenib against advanced hepatocellular carcinoma
Publish place: 1st International Iranian Tissue Engineering and Regenerative Medicine Congress (ITERM2018)
Publish Year: 1397
نوع سند: مقاله کنفرانسی
زبان: English
View: 343
نسخه کامل این Paper ارائه نشده است و در دسترس نمی باشد
- Certificate
- من نویسنده این مقاله هستم
استخراج به نرم افزارهای پژوهشی:
شناسه ملی سند علمی:
ITERMED01_197
تاریخ نمایه سازی: 7 مرداد 1398
Abstract:
Introduction High prevalence of hepatocellular carcinoma (HCC) and typically poor prognosis of this disease lead to late-stage diagnosis when potentially curative therapies are least effective; therefore, development of an effective and systematic treatment is an urgent requirement. Objectives In this study, several current treatments of HCC patients and their advantages or disadvantages were summarized. Moreover, various recent preclinical and clinical studies about the performances of two efficient agents, sorafenib or natural killer (NK) cells , against HCC cells were investigated. In addition, the focus of this review is on the correlation between sorafenib and NK cells and their effects on the performance of each other for better suppression of hepatocellular carcinoma. Results The majority of studies have shown that NK cells and sorafenib could enhance each other s performances and compensated the deficiency of one another in the advanced stages of HCC. However, some studies have reported that sorafenib reduced the number of NK cells and inhibited their proliferation as well as reactivity against HCC cells. This paradoxical effect of this tyrosine kinase inhibitor drug is for its dose and time depending manner. ConclusionFinally, it was concluded that interaction between sorafenib and NK cells is dose and time-dependent, therefore, a careful dose and time optimizing is necessary for the development of a combinational immune-cell therapy. In addition, immunotherapeutic approaches activating NK cells along with sorafenib treatment might improve the outcome of applied treatment for HCC patients.
Keywords:
Authors
Faezeh Hosseinzadeh
Department of Tissue Engineering and Applied Cell Sciences, School of Advanced Technologies in Medicine, Tehran University of Medical Sciences, Tehran, Iran
Javad Verdi
Department of Tissue Engineering and Applied Cell Sciences, School of Advanced Technologies in Medicine, Tehran University of Medical Sciences, Tehran, Iran
Jafar Ai
Department of Tissue Engineering and Applied Cell Sciences, School of Advanced Technologies in Medicine, Tehran University of Medical Sciences, Tehran, Iran
Samad Muhammadnejad
Cancer Biology Research Center, Tehran University of Medical Sciences, Tehran, Iran